1764 Federal Register / Vol. 87, No. 8 / Wednesday, January 12, 2022 / Notices 

1This refers to FDA’s Birth Control Guide 

(https://www.fda.gov/media/150299/download) as 

posted on December 22, 2021 with the exception of 

sterilization surgery for men, which is beyond the 

scope of the WPSI. 

health insurance coverage are required 

to cover specified preventive services 

without a copayment, coinsurance, 

deductible, or other cost sharing, 

including preventive care and 

screenings for women as provided for in 

comprehensive guidelines supported by 

HRSA for this purpose. Private health 

insurance companies must provide this 

coverage without cost-sharing in plan 

years (in the individual market, policy 

years) beginning on or after the date that 

is one year after the date the 

recommendation or guideline is issued. 

A change to the Guidelines is 

considered to be issued on the date on 

which it is accepted by the HRSA 

Administrator. 

Summary of the 2021 Updates 

Recommended by WPSI and Approved 

by HRSA 

Breastfeeding Services and Supplies 

WPSI recommends comprehensive 

lactation support services (including 

consultation, counseling, education by 

clinicians and peer support services, 

and breastfeeding equipment and 

supplies) during the antenatal, 

perinatal, and postpartum periods to 

optimize the successful initiation and 

maintenance of breastfeeding. 

Breastfeeding equipment and supplies 

include, but are not limited to, double 

electric breast pumps (including pump 

parts and maintenance) and breast milk 

storage supplies. Access to double 

electric pumps should be a priority to 

optimize breastfeeding and should not 

be predicated on prior failure of a 

manual pump. Breastfeeding equipment 

may also include equipment and 

supplies as clinically indicated to 

support dyads with breastfeeding 

difficulties and those who need 

additional services. 

Contraception 

WPSI recommends that adolescent 

and adult women have access to the full 

range of contraceptives and 

contraceptive care to prevent 

unintended pregnancies and improve 

health outcomes. Contraceptive care 

includes screening, education, 

counseling, and provision of 

contraceptives (including in the 

immediate postpartum period). 

Contraceptive care also includes followup care (e.g., management, evaluation, 

and changes, including the removal, 

continuation, and discontinuation of 

contraceptives). 

WPSI recommends that the full range 

of U.S. Food and Drug Administration 

(FDA)-approved, -granted, or -cleared 

contraceptives, effective family 

planning practices, and sterilization 

procedures be available as part of 

contraceptive care. The full range of 

contraceptives currently includes those 

listed in the FDA’s Birth Control 

Guide: 1 (1) Sterilization surgery for 

women, (2) implantable rods, (3) copper 

intrauterine devices, (4) intrauterine 

devices with progestin (all durations 

and doses), (5) injectable contraceptives, 

(6) oral contraceptives (combined pill), 

(7) oral contraceptives (progestin only), 

(8) oral contraceptives (extended or 

continuous use), (9) the contraceptive 

patch, (10) vaginal contraceptive rings, 

(11) diaphragms, (12) contraceptive 

sponges, (13) cervical caps, (14) 

condoms, (15) spermicides, (16) 

emergency contraception 

(levonorgestrel), and (17) emergency 

contraception (ulipristal acetate); and 

any additional contraceptives approved, 

granted, or cleared by the FDA. 

Screening for HIV Infection 

WPSI recommends all adolescent and 

adult women, ages 15 and older, receive 

a screening test for human 

immunodeficiency virus (HIV) at least 

once during their lifetime. Earlier or 

additional screening should be based on 

risk, and rescreening annually or more 

often may be appropriate beginning at 

age 13 for adolescent and adult women 

with an increased risk of HIV infection. 

WPSI recommends risk assessment 

and prevention education for HIV 

infection beginning at age 13 and 

continuing as determined by risk. 

A screening test for HIV is 

recommended for all pregnant women 

upon initiation of prenatal care with 

rescreening during pregnancy based on 

risk factors. Rapid HIV testing is 

recommended for pregnant women who 

present in labor with an undocumented 

HIV status. 

Counseling for Sexually Transmitted 

Infections 

WPSI recommends behavioral 

counseling by a health care clinician or 

other appropriately trained individual 

for sexually active adolescent and adult 

women at an increased risk for sexually 

transmitted infections (STIs). 

WPSI recommends that clinicians 

review a woman’s sexual history and 

risk factors to identify those at increased 

risk for STIs. Risk factors include, but 

are not limited to, age younger than 25 

years, a recent history of an STI, a new 

sex partner, multiple partners, a partner 

with concurrent partners, a partner with 

an STI, and a lack of or inconsistent 

condom use. For those without 

identified risk factors, counseling to 

reduce the risk of STIs should be 

considered on an individual basis as 

determined by clinical judgment. 

Well-Woman Preventive Visits 

WPSI recommends that women 

receive at least one preventive care visit 

per year beginning in adolescence and 

continuing across the lifespan to ensure 

the provision of all recommended 

preventive services. The primary 

purpose of well-woman visits is the 

delivery and coordination of 

recommended preventive services as 

determined by age and risk factors. 

These services may be completed at a 

single visit or as part of a series of visits 

that take place over time to obtain all 

necessary services depending on a 

woman’s age, health status, 

reproductive health needs, pregnancy 

status, and risk factors. Well-women 

visits also include pre-pregnancy, 

prenatal, postpartum, and 

interpregnancy visits. 

Preventing Obesity in Midlife Women 

WPSI recommends counseling midlife 

women aged 40 to 60 years with normal 

or overweight body mass index (BMI) 

(18.5–29.9 kg/m2) to maintain weight or 

limit weight gain to prevent obesity. 

Counseling may include individualized 

discussion of healthy eating and 

physical activity. 

Diana Espinosa, 

Acting Administrator. 

[FR Doc. 2022–00465 Filed 1–11–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Indian Health Service 

Request for Public Comment: 30 Day 

Notice for Extension of Fast Track 

Generic Clearance for the Collection of 

Qualitative Feedback on Agency 

Service Delivery: IHS Customer 

Service Satisfaction and Similar 

Surveys 

AGENCY: Indian Health Service, HHS. 

ACTION: Notice and request for 

comments. Request for extension of 

approval. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

Indian Health Service (IHS) invites the 

general public to take this opportunity 

to comment on the information 

collection Office of Management and 

Budget (OMB) Control Number 0917– 

0036, ‘‘Generic Clearance for the 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 8 / Wednesday, January 12, 2022 / Notices 1765 

Collection of Qualitative Feedback on 

Agency Service Delivery.’’ This notice 

announces our intent to submit this 

previously approved information 

collection, which expires January 31, 

2022, to OMB for approval of an 

extension and solicit comments on 

specific aspects for the proposed 

information collection. 

DATES: Consideration will be given to all 

comments received by February 11, 

2022. 

Direct Your Comments To OMB: Send 

your comments and suggestions 

regarding the proposed information 

collection contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time to: Office of Management and 

Budget, Office of Regulatory Affairs, 

New Executive Office Building, Room 

10235, Washington, DC 20503, 

Attention: Desk Officer for IHS. 

FOR FURTHER INFORMATION CONTACT: To 

request additional information, please 

contact Evonne Bennett, Information 

Collection Clearance Officer at: 

Evonne.Bennett@ihs.gov or 301–443– 

4750. 

SUPPLEMENTARY INFORMATION: The IHS is 

submitting the proposed information 

collection to OMB for review, as 

required by the Paperwork Reduction 

Act of 1995, as amended, and its 

implementing regulations. This notice is 

soliciting comments from members of 

the public and affected agencies as 

required by 44 U.S.C. 3507 and 5 CFR 

1320.10 concerning the proposed 

collection of information to: (1) Evaluate 

whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information will have practical utility; 

(2) Evaluate the accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information; (3) Enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Minimize the burden of the collection of 

information on those who are to 

respond; including through the use of 

appropriate automated collection 

techniques of other forms of information 

technology, e.g., permitting electronic 

submission of responses. 

Title: Generic Clearance for the 

Collection of Qualitative Feedback on 

Agency Service Delivery: IHS Customer 

Service Satisfaction and Similar 

Surveys. 

Type of Information Collection 

Request: Three year extension approval 

of this information collection. 

OMB Control Number: 0917–0036. 

Abstract: The proposed information 

collection activity provides a means to 

garner qualitative customer and 

stakeholder feedback in an efficient, 

timely manner, in accordance with the 

Administration’s commitment to 

improving service delivery. Qualitative 

feedback is information that provides 

useful insights on perceptions and 

opinions, but is not statistical surveys 

that yield quantitative results that can 

be generalized to the population of 

study. This feedback will provide 

insights into customer or stakeholder 

perceptions, experiences and 

expectations, provide an early warning 

of issues with service, or focus attention 

on areas where communication, training 

or changes in operations might improve 

delivery of products or services. These 

collections will allow for ongoing, 

collaborative and actionable 

communications between the Agency 

and its customers and stakeholders. It 

will also allow feedback to contribute 

directly to the improvement of program 

management. 

The solicitation of feedback will target 

areas such as: Timeliness, 

appropriateness, accuracy of 

information, courtesy, efficiency of 

service delivery, and resolution of 

issues with service delivery. Responses 

will be assessed to plan and inform 

efforts to improve or maintain the 

quality of service offered to the public. 

If this information is not collected, vital 

feedback from customers and 

stakeholders on the agency’s services 

will be unavailable. 

The agency will only submit a 

collection for approval under this 

generic clearance if it meets the 

following conditions: 

• Information gathered will be used 

only internally for general service 

improvement and program management 

purposes and is not intended for release 

outside of the agency; 

• Information gathered will not be 

used for the purpose of substantially 

informing influential policy decisions; 

• Information gathered will yield 

qualitative information; the collections 

will not be designed or expected to 

yield statistically reliable results or used 

as though the results are generalizable to 

the population of study; 

• The collections are voluntary; 

• The collections are low-burden for 

respondents (based on considerations of 

total burden hours, total number of 

respondents, or burden-hours per 

respondent) and are low-cost for both 

the respondents and the Federal 

Government; 

• The collections are noncontroversial and do not raise issues of 

concern to other Federal agencies; 

• Any collection is targeted to the 

solicitation of opinions from 

respondents who have experience with 

the program or may have experience 

with the program in the near future; and 

• With the exception of information 

needed to provide remuneration for 

participants of focus groups and 

cognitive laboratory studies, personally 

identifiable information (PII) is 

collected only to the extent necessary 

and is not retained. 

Feedback collected under this generic 

clearance provides useful information, 

but it does not yield data that can be 

generalized to the overall population. 

This type of generic clearance for 

qualitative information will not be used 

for quantitative information collections 

that are designed to yield reliably 

actionable results, such as monitoring 

trends over time or documenting 

program performance. Such data uses 

require more rigorous designs that 

address: The target population to which 

generalizations will be made, the 

sampling frame, the sample design 

(including stratification and clustering), 

the precision requirements or power 

calculations that justify the proposed 

sample size, the expected response rate, 

methods for assessing potential nonresponse bias, the protocols for data 

collection, and any testing procedures 

that were or will be undertaken prior to 

fielding the study. Depending on the 

degree of influence the results are likely 

to have, such collections may still be 

eligible for submission for other generic 

mechanisms that are designed to yield 

quantitative results. 

As a general matter, information 

collections will not result in any new 

system of records containing privacy 

information and will not ask questions 

of a sensitive nature, such as sexual 

behavior and attitudes, religious beliefs, 

and other matters that are commonly 

considered private. 

Current Actions: Extension of 

approval for a collection of information. 

Type of Review: Extension. 

Affected Public: Individuals and 

households, businesses and 

organizations, and Tribal governments. 

Estimated Number of Respondents: 

105,000. 

Below are projected annual average 

estimates for the next three years: 

Average Expected Annual Number of 

Activities: 100. 

Average number of Respondents per 

Activity: 1,050. 

Annual responses: 105,000. 

Frequency of Response: Once per 

request. 

Average minutes per response: 10. 

Burden hours: 17,500. 

There are no direct costs to 

respondents to report. 

An agency may not conduct or 

sponsor, and a person is not required to 


lotter on DSK11XQN23PROD with NOTICES1
1766 Federal Register / Vol. 87, No. 8 / Wednesday, January 12, 2022 / Notices 

respond to, a collection of information 

unless it displays a currently valid OMB 

control number. 

Comment Due Date: Your comments 

regarding this information collection are 

best assured of having full effect if 

received within 30 days of the date of 

this publication. 

Elizabeth A. Fowler, 

Acting Deputy Director, Indian Health 

Service. 

[FR Doc. 2022–00364 Filed 1–11–22; 8:45 am] 

BILLING CODE 4165–16–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; NonPharmacological Clinical Trials. 

Date: February 8, 2022. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Regina Tousignant DolanSewell, Division of Extramural Activities, 

National Institute of Mental Health, NIH, 

Neuroscience Center, 6001 Executive Blvd., 

Room 4154, MSC 9606, Bethesda, MD 20852, 

regina.dolan-sewell@nih.gov 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Service Ready Tools for Suicide Prevention. 

Date: February 11, 2022. 

Time: 10:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Nicholas Gaiano, Ph.D., 

Review Branch Chief, Division of Extramural 

Activities, National Institute of Mental 

Health, NIH, Neuroscience Center/Room 

6150/MSC 9606, 6001 Executive Boulevard, 

Bethesda, MD 20892–9606, 301–443–2742, 

nick.gaiano@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: January 6, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–00431 Filed 1–11–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute on 

Aging Special Emphasis Panel, February 

14, 2022, 1:00 p.m. to 3:30 p.m., 

National Institute on Aging, Gateway 

Building, 7201 Wisconsin Avenue, Suite 

2W200, Bethesda, MD 20892, which 

was published in the Federal Register 

on December 16, 2021, FR Doc 2021– 

27280, 86 FR 71512. 

The meeting notice is amended to 

change the date of the meeting from 

February 14, 2022 to February 24, 2022. 

The meeting is closed to the public. 

Dated: January 7, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–00483 Filed 1–11–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Acquired 

Resistance to Therapy Network (ARTNet). 

Date: February 16–17, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W124, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: David G. Ransom, Ph.D., 

Chief, Scientific Review Officer, Special 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W124, 

Rockville, Maryland 20850, 240–276–6351, 

david.ransom@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; TEP–9: 

Contract Review Meeting. 

Date: February 25, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W236, Rockville, Maryland 20850, 

(Telephone Conference Call). 

Contact Person: Shuli Xia, Ph.D., Scientific 

Review Officer, Research Technology and 

Contract Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH 9609 Medical Center Drive, 

Room 7W236 Rockville, Maryland 20850 

240–276–5256 shuli.xia@nih.gov 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; TEP–4: 

SBIR Contract Review Meeting. 

Date: March 3–4, 2022. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W106, Rockville, Maryland 20850 

(Telephone Conference Call), 

Contact Person: Eduardo Emilio Chufan, 

Ph.D., Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W106, Rockville, Maryland 

20850, 240–276–7975, chufanee@

mail.nih.gov, 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; TEP–8: 

Contract Review Meeting. 

Date: March 4, 2022. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W236, Rockville, Maryland 20850, 

(Telephone Conference Call). 

Contact Person: Shuli Xia, Ph.D., Scientific 

Review Officer Research Technology and 

Contract Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W236, Rockville, Maryland 20850, 

240–276–5256 shuli.xia@nih.gov. 


lotter on DSK11XQN23PROD with NOTICES1